Yichang Changjiang Pharmaceutical Co., Ltd. and Yidu Dongyangguang Biochemical Pharmaceutical Co., Ltd. are located in Yidu City, Hubei Province on the bank of the Yangtze River.
The Yidu base currently produces more than 40 APIs and preparations, including the third company in the world authorized by the Swiss company Roche to produce the anti-influenza drug "oseltamivir phosphate capsules" and the world's exclusive dosage form of "oseltamivir phosphate granules".
In addition, the drug Oumeining (telmisartan tablets) is used to treat high blood pressure, the drug Ertongshu (benbromarone tablets) is used to prevent and treat hyperuricemia, and the allergy treatment drug Xining (Xining) is the only domestically produced dosage form. Cetirizine hydrochloride dispersible tablets), azithromycin dispersible tablets, azithromycin capsules, azithromycin dry suspension, clarithromycin dispersible tablets, roxithromycin tablets, levofloxacin lactate tablets, fluconazole capsules, simvastatin tablets, benzene sulfonate Amlodipine tablets, lisinopril tablets, matrine dispersible tablets, tiopronin tablets, valacyclovir hydrochloride tablets, ganciclovir for injection, mycophenolate mofetil for injection and Ozaclovir for injection Gray, etc., are all products with proven efficacy and good market sales.
Yidu Dongyangguang Biochemical Pharmaceutical Co., Ltd. mainly produces pharmaceutical APIs. It is currently the largest macrolide biochemical API base in China. In 2009, its sales revenue ranked 29th in the Chinese pharmaceutical industry. Dongyangguang Biochemical Pharmaceutical has the world's largest monomer fermentation tanks, of which three ultra-large volume fermentation tanks (volume 372M) use the amplification technology of flow field characteristics research to produce macrolide APIs with world-leading quality. The company has made continuous breakthroughs in the research and development technology of macrolide APIs, independently developed a new erythromycin production process, and has applied for a patent from the State Intellectual Property Office.
The Yidu base currently has 4 APIs that have passed the cGMP certification of the European Union. In 2009, macrolide products passed the cGMP certification of the US FDA. The base also undertakes the national 863 project and is a national 863 project. Leading unit of fermentation technology.